DBV Technologies Q3 2026 Results and Business Update Conference Call - DBV TECHNOLOGIES SA

Explicit Guidance:

• Cash Runway: Existing cash balance of $165.7 million is projected to fund operations through the third quarter of 2027, based on a stage-gated, milestone-based investment approach aligned with regulatory developments.
• Operating Expenses: FY 2026 Q3 opex was $164.4 million (up $59.4 million YoY); future spending will be paced to regulatory milestones, specifically funding FDA review and launch infrastructure (medical affairs, market access, marketing, account management, pharmacovigilance).
• Sales Force Build-out: Targeting a U.S. sales force of 50–70 representatives to cover approximately 4,500 allergists.
• Inventory: Continued investment in pre-commercial inventory to support launch readiness.
• Second Manufacturing Capacity: Identification of a second manufacturing unit required for supply beyond the initial years of the forecast; timeline for facility setup estimated at ~3 years.

Business-Segment Outlook:

• BLA 4–7 Years: Submitted BLA for ages 4–7; targeting a Priority Review decision based on Breakthrough Therapy designation; planning assumes a tight Priority Review timeline without extra buffer.
• BLA 1–3 Years (Toddlers): Expect to submit the BLA for ages 1–3 in 2027; submission will follow the review of the 4–7 BLA to avoid creating a regulatory bottleneck, allowing the FDA to leverage learnings from the first review.
• Acquisition Pathway: Accelerated Approval Pathway confirmed for toddlers (1–3 years); Breakthrough designation eligibility for Priority Review confirmed for 4–7 years, with potential eligibility for 1–3 years depending on agency alignment.
• Clinical Data: The "COMFORT Toddler" supplemental safety study (6-month duration) is complete; results expected to be "check-the-box" regarding safety, with no anticipated deviations from historical data.
• Commercial Strategy: Marketing and payer engagement efforts (health economic outcome research, prioritization processes) are ongoing; launch preparation requires approximately 18 months of planning.

Market and Competitive Outlook:

• Competitive Landscape: Viaskin Peanut Patch is described as a "novel" drug-device combination with no direct analogs; unique biology and mode of action.
• Payer Dynamics: Engagement with major U.S. payers is active; pricing discussions aim for a "fair" price with a prioritization process expected to be relatively straightforward due to the product's nature.
• Market Size: Target population for the 4–7 age group is approximately 250,000 to 300,000 children; the 1–3 age group is slightly smaller.

Macro / Industry Outlook:

• Regulatory Environment: FDA review process is described as "constructive"; the agency has agreed to a sequential review approach for the two BLAs to ensure efficiency.
• Manufacturing Standards: Remediation of warning letter issued to CMO Fareva (April 2026) is ongoing; FDA re-inspection not yet scheduled but anticipated to occur after remediation completion.
• Regulatory Vouchers: Company determined likely ineligible for Priority Review Voucher monetization as the technology is intended for use across multiple age groups (1–7 years), violating the strict "single population" rule for voucher eligibility.

Strategic Initiatives:

• Remediation Process: Fareva has submitted a detailed remediation plan to the FDA within 15 days; DBV and third-party consultants are actively monitoring progress with monthly updates provided to the FDA.
• Pre-Approval Inspection (PAI): PAI readiness target date set for February 1, 2027; mock PAIs will be conducted leading up to this date.
• Capacity Expansion: Investment in a second manufacturing site planned to support "full flight" of the product post-approval (not intended as an immediate backup for Fareva).
• Rolling Submission Strategy: Exploring sequential submission of 1–3 BLA to align with FDA efficiency goals rather than parallel submission.

Risks and Headwinds to Outlook:

• Regulatory Review Bottleneck: Potential risk of review delays if two BLAs are submitted in parallel; mitigated by agreed sequential approach.
• Manufacturing Remediation Success: Outstanding reliance on Fareva's successful completion of site-wide remediation prior to FDA re-inspection.
• Priority Review Uncertainty: While expected, Priority Review for the 4–7 BLA is a hope/expectation, not a guaranteed commitment from the FDA.
• Timeline Sensitivity: Launch and operational planning are "hinged" on the Priority Review clock; no buffer time has been added to plans.
• Supply Chain: Need for a second manufacturer remains a multi-year strategic gap (approx. 3 years) to establish redundant capacity.

Management Tone on the Future:

• Confidence: High confidence in the remediation progress and the FDA's constructive engagement; describes the approach as "disciplined execution."
• Urgency: Emphasis on "expedient and efficient" review; planning assumes the best-case scenario (tight timeline) to maximize efficiency.
• Strategic Focus: Shift from pure clinical development to "becoming a commercial company," with significant investment in commercial infrastructure (sales, marketing, medical affairs) prior to launch.
• Transparency: Commitment to providing updates as key regulatory milestones (re-inspection, submission dates) are reached.

Miscellaneous:

• ATM Program: $50 million in gross proceeds received from ADs sales to RA Capital under a refreshed At-The-Market (ATM) program.
• FDA Interaction: FDA review of the BLA and the remediation of the Fareva warning letter are distinct processes that converge only at the Pre-Approval Inspection (PAI) stage.